Active, not recruitingPhase 3NCT05118776

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Studying Giant cell glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ascletis Pharmaceuticals Co., Ltd.
Intervention
ASC40 tablets(drug)
Enrollment
136 enrolled
Eligibility
18 years · All sexes
Timeline
20222025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05118776 on ClinicalTrials.gov

Other trials for Giant cell glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Giant cell glioblastoma

← Back to all trials